05:27:46 EDT Mon 15 Aug 2022
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
M Pharmaceutical Inc (2)
Symbol MQ
Shares Issued 14,237,343
Close 2015-10-14 C$ 0.08
Recent Sedar Documents

M Pharmaceutical appoints Kulick as development adviser

2015-10-15 09:14 ET - News Release

Mr. Matthew Lehman reports

M PHARMACEUTICAL, INC. ENGAGES ROY M. KULICK, MD AS CLINICAL DEVELOPMENT ADVISOR

M Pharmaceutical Inc. has engaged Dr. Roy M. Kulick, MD, as clinical development adviser. Dr. Kulick will prepare clinical trial plans for the company's lead product, Trimeo, which are capsules for the treatment of obesity.

"I am pleased that Dr. Kulick has agreed to join M Pharmaceutical at this crucial time as we plan for the clinical development of Trimeo," said the company's chief executive officer, Matthew Lehman. "I believe his clinical development experience will prove beneficial to our growth plans."

Dr. Kulick is an MBA-trained physician with a record of success in clinical research, life sciences start-ups and regulatory strategy. After receiving his MD from the University of Pennsylvania School of Medicine, Dr. Kulick has served in a number of academic and industry roles including division director at Cincinnati Children's Hospital; executive director of Schuman Associates IRB; senior scientist at the Proctor & Gamble Co., where he led clinical evaluation of weight management technologies; and director of clinical research at Ethicon Endo-Surgery (a Johnson & Johnson Company). Currently, Dr. Kulick is an entrepreneur-in-residence at the University of Cincinnati technology accelerator for commercialization and at the University of Louisville Coulter translational partnership as well as the principal of ConneXion Life Sciences.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.